The Academy of Managed Care Pharmacy (AMCP) is writing to express its opposition to certain provisions of H.B. No. 254. AMCP opposes the practitioner notification requirements, which would place an unnecessary burden on the substitution of an interchangeable biological drug product. In addition, AMCP also opposes the new definition of “interchangeable biological product” included in the bill, which is not consistent with the Food and Drug Administration (FDA) definition.
The Academy of Managed Care Pharmacy (AMCP) is writing to express our concerns with Section 11 of S. 2700, the “FDA and NIH Workforce Authorities Modernization Act,” which was considered by the Senate Health, Education, Labor and Pensions Committee and placed on the Senate calendar on April 18th. This section of the bill states that “provisions of the Federal Food, Drug, and Cosmetic Act that refer to an official compendium as defined under section 201(j) of such Act shall not apply to a biological product subject to regulation under this section.”
The Academy of Managed Care Pharmacy (AMCP) thanks the Centers for Medicare and Medicaid Services (CMS) Center for Medicare and Medicaid Innovation (CMMI) for the opportunity to provide comments in response to the memorandum titled “Request for Public Comment on the Proposed Enhanced MTM Model Encounter Data Structure and Pilot Monitoring Measures” released on February 26, 2016.
Press Release: The Academy of Managed Care Pharmacy (AMCP) Foundation is proud to announce the recipients of its 16th Annual National Student Pharmacist Pharmacy & Therapeutics Competition (P&T) and 2016 Best Student Pharmacist Poster and Best Resident or Fellow Poster Contests.
Press Release: More than 4,200 managed care pharmacists and other health care professionals from across the country are gathered in San Francisco, Calif., this week to attend the Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy Annual Meeting.
Press Release: Managed care pharmacy will recognize its most distinguished leaders this evening at the Annual Awards Dinner of the Academy of Managed Care Pharmacy (AMCP) and AMCP Foundation.
Press Release: Patients with high cholesterol should use proven and less expensive therapies, such as statins, before trying the new and more expensive class of specialty cholesterol drugs known as PCSK9 inhibitors.
The language in S. 1913 now included as part of S. 524 strikes the appropriate balance of prospectively identifying at-risk beneficiaries and help them obtain the necessary treatment sooner to address addictions potential abuse while simultaneously preserving a beneficiaries’ rights to be notified, submit their preferences for prescriber and pharmacy, and exercise appeals.